UB Paderborn / Katalog / Suche / in CDI

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood, 2020-05, Vol.135 (22), p.1929-1945

2020

Volltextzugriff (PDF)

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

Blood, 2014-07, Vol.124 (4), p.483-492

2014

Volltextzugriff (PDF)

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

Nature medicine, 2021-12, Vol.27 (12), p.2192-2199

2021

Volltextzugriff (PDF)

Glasdegib in newly diagnosed acute myeloid leukemia

Expert review of anticancer therapy, 2021-06, Vol.21 (6), p.573-581

2021

Volltextzugriff (PDF)

Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs

Cancer research (Chicago, Ill.), 2008-10, Vol.68 (19), p.8031-8038

2008

Volltextzugriff (PDF)

Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F

Journal of clinical oncology, 2015-11, Vol.33 (33), p.3953-3960

2015

Volltextzugriff (PDF)

Saving orphans: BRAF targeting of histiocytosis

Blood, 2013-02, Vol.121 (9), p.1487-1488

Heaney, Mark L.

2013

Volltextzugriff (PDF)

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

Clinical cancer research, 2010-11, Vol.16 (21), p.5303-5311

2010

Volltextzugriff (PDF)

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

Journal of clinical oncology, 2006-01, Vol.24 (1), p.166-173

2006

Volltextzugriff (PDF)

A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia

Nucleic acids research, 2011-03, Vol.39 (6), p.2458

2011

Volltextzugriff (PDF)

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Blood advances, 2020-09, Vol.4 (18), p.4282-4291

2020

Volltextzugriff (PDF)

Zeroing in on cereblon

European journal of haematology, 2015-07, Vol.95 (1), p.1-2

Heaney, Mark L.

2015

Volltextzugriff (PDF)

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

Journal of clinical oncology, 2005-06, Vol.23 (17), p.3923-3931

2005

Volltextzugriff (PDF)

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

Blood, 2008-06, Vol.111 (11), p.5350-5358

2008

Volltextzugriff (PDF)

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

Haematologica (Roma), 2018-01, Vol.103 (1), p.e5

2018

Volltextzugriff (PDF)

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

Blood, 2008-10, Vol.112 (7), p.2906-2916

2008

Volltextzugriff (PDF)

Myelodysplasia

The New England journal of medicine, 1999-05, Vol.340 (21), p.1649-1660

1999

Volltextzugriff (PDF)

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera

HemaSphere, 2022-06, Vol.6 (6), p.e721-n/a

2022

Volltextzugriff (PDF)

Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest

Clinical advances in hematology & oncology, 2014-08, Vol.12 (8), p.502-508

Heaney, Mark L

2014

Volltextzugriff (PDF)

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis

Pediatric blood & cancer, 2017-05, Vol.64 (5), p.np-n/a

2017

Volltextzugriff (PDF)

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms

Blood advances, 2018-12, Vol.2 (24), p.3572-3580

2018

Volltextzugriff (PDF)

Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses

Journal of clinical oncology, 2009-02, Vol.27 (4), p.491-497

2009

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial

Glasdegib in newly diagnosed acute myeloid leukemia

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis

Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F

Saving orphans: BRAF targeting of histiocytosis

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies

A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Zeroing in on cereblon

Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies

Myelodysplasia

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera

Sequencing treatment in chronic myeloid leukemia: the first choice may be the hardest

Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase

A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms

Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete Responses

Suchergebnisse filtern